Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00004129

Trial Description

start of 1:1-Block title

Title

Randomized, Double-blind, Placebo-controlled, Parallel Group Study of Vardenafil 10 mg Twice Daily to Assess the Effect on Urodynamics in Patients With Overactive Bladder (Detrusor Overactivity)

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The purpose of this study is to assess if the study drug, Vardenafil (approved by Health
Authorities is available on the market for treatment of erectile dysfunction) has an effect
on bladder function and micturition frequency. The study drug is to be taken in the form of
tablets twice a day, one tablet in the morning and one tablet in the evening. A non-active
treatment (placebo), a sugar pill, will be used as a comparator to see if the new study drug
works better than no drug. The timing of visits for the study is as follows: the 1st visit
(screening visit) at beginning of run-in-assessment with qualifying tests for patients:
electrocardiogram (ECG), safety laboratory and residual urine (by ultrasonography: a
non-invasive examination using ultrasound for the assessment of the bladder). 2nd visit
(randomization visit). During visit this should be performed: urodynamic measurements
(filling cystometry and pressure flow investigations), ECG and safety laboratory. 3rd visit
(safety visit) takes place at two up to three weeks of randomized treatment. 4th visit
(final visit)-following test should be done: urodynamic measurements (filling cystometry and
pressure flow investigations), ECG, safety laboratory and residual urine (by
ultrasonography); A phone call 24 hours after visit 4 to assess any SAEs.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

[---]*

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00004129
  •   2013/01/10
  •   2007/05/24
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2006-005145-11 
  •   NCT00478881  (ClinicalTrials.gov)
  •   12392  (Bayer)
  •   2006-005145-11 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Overactive Bladder
  •   Detrusor Overactivity
  •   N32.8 -  Other specified disorders of bladder
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Vardenafil HCl (Levitra, BAY38-9456)
  •   Drug: Placebo
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, caregiver, investigator/therapist
  •   Placebo
  •   Treatment
  •   Parallel
  •   II
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Change From Baseline in Bladder Volume at First Detrusor Contraction at 6 Weeks; time frame: baseline and up to 6 weeks of treatment Last Observation Carried Forward (LOCF); Bladder volume was measure by means of urodynamic assessments (cystometry) for up to 6 weeks. Missing data were imputed with last observation carried forward (LOCF).
- Change From Baseline in Average Number of Daily Micturitions at 6 Weeks; time frame: baseline and up to 6 weeks of treatment LOCF; Change from baseline in the number of daily micturitions (bladder voidings), as reported in the participant diaries for up to 6 weeks. Missing data were imputed with last observation carried forward (LOCF).

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Change From Baseline in H2O Detrusor Pressure at First Contraction at 6 Weeks; time frame: baseline and up to 6 weeks of treatment LOCF; Detrusor pressure was measured by means of urodynamic assessment (cystometry) for up to 6 weeks. Missing data were imputed by last observation carried forward (LOCF).
- Change From Baseline in Volume at First Detectable Leakage at 6 Weeks; time frame: baseline and up to 6 weeks of treatment LOCF; First detectable leakage was determined by means of cystometry as an obligatory urodynamic measure. Missing data was imputed by last observation carried forward (LOCF).
- Change From Baseline in Maximum Cystometric Bladder Capacity at 6 Weeks; time frame: baseline and up to 6 weeks of treatment LOCF; Maximum cystometric bladder capacity was defined as the volume at which either significant leakage or discomfort/pain occurred. Missing data were imputed by last observation carried forward (LOCF).
- Change From Baseline in Volume at First Desire to Void at 6 Weeks; time frame: baseline and up to 6 weeks of treatment LOCF; Volume at first desire to void was recorded during urodynamic assessments. Missing data were imputed by last observation carried forward (LOCF).
- Change From Baseline in Average Number of Urgencies Per Day at 6 Weeks; time frame: baseline and up to 6 weeks of treatment LOCF; The average number of urgencies was derived from the number of urgencies reported by the participants in a 7 day micturition diary. Missing data were imputed by last observation carried forward.
- Change From Baseline in Average Number of Daily Involuntary Discharges of Urine at 6 Weeks; time frame: baseline and up to 6 weeks of treatment LOCF; The average number of daily involuntary discharges of urine was derived from the number of discharges reported by the participants in a 7 day micturition diary. Missing data were imputed by last observation carried forward.
- Change From Baseline in Peak Urinary Flow at 6 Weeks in Men Aged 50 Years and Older; time frame: baseline and up to 6 weeks of treatment LOCF; Peak urinary flow (Qmax) was measured using urodynamic assessments (voiding / flow cystometry) for up to 6 weeks. Missing data were imputed by last observation carried forward (LOCF).
- Change From Baseline in the Total Score of the Overactive Bladder Questionnaire (OAB-q) at 6 Weeks; time frame: baseline and up to 6 weeks of treatment LOCF; The OAB-q is a validated, self-administered questionnaire that quantifies bladder symptoms and quality of life. It comprises 33 items (6-point scale for each item). The total score ranges from 33 (minimum symptoms) to 198 (maximum symptoms). On each item, participants provide their rating over the past 4 weeks. Missing data were imputed by LOCF.

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Belgium
  •   Canada
  •   Czech Republic
  •   France
  •   Germany
  •   Hungary
  •   Israel
  •   Netherlands
  •   Poland
  •   Portugal
  •   Russian Federation
  •   Spain
  •   Switzerland
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2007/08/31
  •   397
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Male and female patients aged > 18 years (females either postmenopausal or using
adequate birth control)

- Urodynamic criteria:

- Entire bladder capacity (= maximum cystometric bladder capacity) < 300 mL OR

- In accordance with International Continence Society (ICS)-guidelines: Detrusor
overactivity as defined as spontaneous involuntary detrusor contraction during
filling phase OR

- Detrusor contraction during filling phase leading to involuntarily initiated
micturition before a normal bladder capacity is reached

- Patient micturition diary criteria: at least 8 micturitions per day AND at least 1
urgency episode per day

- Signed and dated written Patient Informed Consent Form

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Treatment with drugs known to affect urinary bladder function

- Known other reasons for micturition problems than detrusor overactivity

- Recent intervention in urogenital tract

- Abnormal liver or renal lab values

- Treatment with nitrates or nitric oxide donors, alpha-blockers, potent inhibitors of
CYP-450 3A4, acenocoumarol, heparin, drugs known to prolong QT-interval

- NAION, hereditary regenerative retinal disorders, severe cardiovascular conditions,
recent history of myocardial infarction/stroke/life-threatening arrhythmia

- congenital QT-prolongation, left ventricular outflow obstruction, severe hypo- or
hypertension, symptomatic postural hypotension

- History of positive test for Hepatitis B surface antigen (HBsAg) or Hepatitis C

- Significant active peptic ulceration

- Severe chronic or acute liver disease, history of moderate (Child-Pugh B) or severe
(Child-Pugh C) hepatic impairment

- In men: Clinically significant chronic haematological disease which may lead to
priapism

- History of malignancy of any organ system within the past 5 years

- Bleeding disorder

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Bayer
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Bayer
    • Bayer Study Director 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Bayer
    • Bayer Study Director 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up complete
  •   2008/11/01
end of 1:1-Block state
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   5
  •   2016/01/14


* This entry means the parameter is not applicable or has not been set.